{"id":"W1987135361","doi":"10.1093/neuonc/noq016","title":"Temozolomide and MGMT forever?","year":2010,"lang":"en","type":"editorial","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Temozolomide; Medicine; Dacarbazine; Oncology; Internal medicine; Clinical trial; Glioma; Chemotherapy; Clinical endpoint; Progression-free survival; Cancer; Phases of clinical research; Cancer research","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002190268,0.0005486092,0.0009587248,0.0006730208,0.0007232033,0.002733741,0.00125068,0.005905409,0.01039947],"category_scores_gemma":[0.005288659,0.0002813884,0.000447006,0.0006271618,0.001993655,0.005016559,0.001168442,0.008037372,0.004605791],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001336401,"about_ca_system_score_gemma":0.001344969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007316609,"about_ca_topic_score_gemma":0.002278556,"domain_scores_codex":[0.9990125,0.0001998389,0.00009037812,0.0001772736,0.0003981488,0.0001219157],"domain_scores_gemma":[0.9972881,0.0009800514,0.0004024759,0.0001696059,0.0005470973,0.0006126772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003601382,0.00007329596,0.0007086712,0.000510581,0.00004653713,0.0004349566,0.00009494751,0.00007367251,0.00102106,0.01040284,0.7576384,0.2286349],"study_design_scores_gemma":[0.00003803939,0.00006468831,0.0005387883,0.0002096171,0.00002501662,0.0004461812,0.00007903231,0.00005920076,0.0003479955,0.006659106,0.991522,0.00001035362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.00202234,0.2229455,0.0006827218,0.6764834,0.08804048,0.00002623327,0.0001441736,0.0000845892,0.009570562],"genre_scores_gemma":[0.01868553,0.1802641,0.0008673107,0.4800531,0.2883511,0.00004721158,0.0002489011,0.0001003711,0.03138246],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.01039947,"threshold_uncertainty_score":0.03478968,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01264403009274546,"score_gpt":0.3051382854290138,"score_spread":0.2924942553362684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}